Archive for August 2023

Like last year, just over 150 companies from the Bay State made the Inc. 5000 list, the financial magazine’s annual ranking of the fastest-growing privately held companies in the U.S. Read More

Talk of the bans has roiled restaurateurs. Many claim that gas cooking is essential to food quality, calling a ban a threat to their business. Read More

The state began getting in touch Tuesday with more than 134,000 people currently or previously enrolled in certain state programs whose personal information, potentially including private medical details and financial data, was part of a data breach involving a file transfer program used by the UMass Chan Medical School. Read More

A Newton biotech has just a few weeks of cash runway as it struggles to commercialize its recently approved urea cycle disorder drug. Read More

Less than two months after two lawyers left Boston IP law firm Sunstein LLP to join Boston-based Burns & Levinson, Sunstein has returned the favor, scooping up a former Burns lawyer to join its litigation practice group. Read More

CEO Sam Ryan said Zeelo’s business is on track to quadruple compared to 2022 with its U.S. expansion. The company has already secured clients like Boston-based Fidelity. Read More

Good morning, and happy National Lemon Meringue Pie Day. Here are the five things you need to know in Boston business news to start your rainy workday, plus Good News Tuesday, a record condo sale, a Woodstock anniversary and an exit interview with a CEO I’ve known over 15 years. Read More

Tufts Medicine will cut hundreds of jobs after selling its outreach laboratory business to Labcorp, with the intention that employees get comparable offers. Read More

The state Department of Energy Resources gave its support to Commonwealth Wind’s push to pay $48 million and back out of its previous agreements with utility companies for the project, a move that would clear the way for developer Avangrid to pursue more favorable terms in a new round of bidding. Read More

HilleVax Inc., the biotech that pulled off Boston’s largest IPO of 2022, is delaying its norovirus vaccine by several months. CEO Rob Hershbeg cited logistical issues as reason for the delay. Read More